A

ALX Oncology Holdings Inc. (ALXO)

NMS – Real vaqt narxi. Valyuta: USD

2.03

-0.05 (-2.40%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

ALX Oncology Holdings Inc. (ALXO)

NMS – Real vaqt narxi. Valyuta: USD

2.03

-0.05 (-2.40%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

09.05.2026

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

08.05.2026

ALX Oncology Q1 Earnings Call Highlights

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.

08.05.2026

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

07.05.2026

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

30.04.2026

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.

17.04.2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology's common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

Videolar

No Data

There is no data to display

Press-relizlar

08.05.2026

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

07.05.2026

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

30.04.2026

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.

17.04.2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology's common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

Search stocks

ALX Oncology Holdings Inc. (ALXO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

ALX Oncology Holdings Inc. (ALXO)

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

ALX Oncology Q1 Earnings Call Highlights

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Videolar

No Data

Press-relizlar

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules